BACKGROUND: Current guidelines call for high-intensity statin therapy in patients with cardiovascular disease on the basis of several previous “more versus less statins” trials. However, no clear evidence for more versus less statins has been established in an Asian population.

METHODS: In this prospective, multicenter, randomized, open-label, blinded end point study, 13,054 Japanese patients with stable coronary artery disease who achieved low-density lipoprotein cholesterol (LDL-C) <120 mg/dL during a run-in period (pitavastatin 1 mg/d) were randomized in a 1-to-1 fashion to high-dose (pitavastatin 4 mg/d; n=6526) or low-dose (pitavastatin 1 mg/d; n=6528) statin therapy. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization. The secondary composite end point was a composite of the primary end point and clinically indicated coronary revascularization excluding target-lesion revascularization at sites of prior percutaneous coronary intervention.

RESULTS: The mean age of the study population was 68 years, and 83% were male. The mean LDL-C level before enrollment was 93 mg/dL with 91% of patients taking statins. The baseline LDL-C level after the run-in period on pitavastatin 1 mg/d was 87.7 and 88.1 mg/dL in the high-dose and low-dose groups, respectively. During the entire course of follow-up, LDL-C in the high-dose group was lower by 14.7 mg/dL than in the low-dose group (P<0.001). With a median follow-up of 3.9 years, high-dose as compared with low-dose pitavastatin significantly reduced the risk of the primary end point (266 patients [4.3%] and 334 patients [5.4%]; hazard ratio, 0.81; 95% confidence interval, 0.69–0.95; P=0.01) and the risk of the secondary composite end point (489 patients [7.9%] and 600 patients [9.7%]; hazard ratio, 0.83; 95% confidence interval, 0.73–0.93; P=0.002). High-dose pitavastatin also significantly reduced the risks of several other secondary end points such as all-cause death, myocardial infarction, and clinically indicated coronary revascularization. The results for the primary and the secondary composite end points were consistent across several prespecified subgroups, including the low (<95 mg/dL) baseline LDL-C subgroup. Serious adverse event rates were low in both groups.

CONCLUSIONS: High-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in Japanese patients with stable coronary artery disease.

CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01042730.
Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for cardiovascular events, and lowering LDL-C with statins has proved effective for primary and secondary prevention of coronary artery disease (CAD). Several previous “more versus less statins” trials in patients with CAD demonstrated that high-intensity statin therapy significantly reduced cardiovascular events compared with moderate-intensity statin therapy. REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) is currently the largest randomized trial to compare high-dose and low-dose statin therapy. It was also the first such trial performed in Asia. High-dose compared with low-dose pitavastatin significantly reduced the primary end point (a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization). All-cause death, myocardial infarction, and clinically indicated coronary revascularization were also significantly reduced. Rates of serious adverse events were similar in the 2 treatment groups.

What Are the Clinical Implications?

- The results of the REAL-CAD study confirmed that high-dose compared with low-dose pitavastatin can safely improve the prevention of cardiovascular events in Japanese patients with coronary artery disease, who commonly receive low-intensity statin therapy.
- REAL-CAD is a practice-changing trial, suggesting that the administration of maximum tolerable doses of statins, within the range of local approval, would be the preferred statin strategy in patients with established coronary artery disease regardless of baseline low-density lipoprotein cholesterol levels.

**Clinical Perspective**

**What Is New?**

- REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) is currently the largest randomized trial to compare high-dose and low-dose statin therapy.
- It was also the first such trial performed in Asia.
- High-dose compared with low-dose pitavastatin significantly reduced the primary end point (a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization).
- All-cause death, myocardial infarction, and clinically indicated coronary revascularization were also significantly reduced.
- Rates of serious adverse events were similar in the 2 treatment groups.

**METHODS**

The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

**Study Design**

The REAL-CAD study (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) is a prospective, multicenter, randomized, open-label, blinded end point, physician-initiated superiority trial to determine whether high-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy could reduce cardiovascular events in Japanese patients with stable CAD. Pitavastatin is a statin with potent LDL-C-lowering effects developed by Kowa Pharmaceutical Co Ltd (Tokyo, Japan). Pitavastatin doses of 1 and 4 mg were reported to reduce LDL-C by 33.6% and 47.2%, respectively, in Japanese patients. A similar magnitude of LDL-C reduction was also reported in white and East Asian patients. Pitavastatin 4 mg is the maximum approved dose in Japan and has demonstrated effects comparable to atorvastatin 20 mg in terms of both LDL-C reduction and coronary plaque regression assessed by intravascular ultrasound, whereas pitavastatin 1 mg has an LDL-C-lowering effect comparable to that of atorvastatin 5 mg.

Eligible patients were men and women 20 to 80 years of age with stable CAD as defined by a history of acute coronary syndrome or coronary revascularization ≥3 months ago or a clinical diagnosis of CAD with angiographically documented coronary artery stenosis of at least 75% diameter narrowing according to the American Heart Association classification. We excluded those patients with LDL-C <100 mg/dl without statin therapy before enrollment because the label in the instructions for pitavastatin restricted use to patients with hypercholesterolemia. Detailed inclusion and exclusion criteria are provided in the online-only Data Supplement. Patients were enrolled on an outpatient basis through academic and general hospitals and clinics across Japan. Eligible patients who provided informed consent were enrolled and received pitavastatin 1 mg once daily orally for a run-in period of at least 1 month. Patients were evaluated for secondary eligibility, excluding those patients with LDL-C ≥120 mg/dl after the run-in period, onset of acute coronary syndrome and/or coronary revascularization within the past 3 months, poor medication adherence to pitavastatin, occurrence of primary end point events, or adverse events prohibiting study continuation during the run-in period.

Patients who met the secondary eligibility criteria were randomized in a 1:1-to-1 fashion to oral pitavastatin, either 4 mg/d (high-dose group) or 1 mg/d (low-dose group), with an electronic data capture system and dynamic allocation stratified by facility, age (<65 or ≥65 years), sex, diabetes mellitus, and statin use before enrollment. The assignment algorithm was made available to other researchers for purposes of reproducing the results or replicating the procedure.

**What Are the Clinical Implications?**

- The results of the REAL-CAD study confirmed that high-dose compared with low-dose pitavastatin can safely improve the prevention of cardiovascular events in Japanese patients with coronary artery disease, who commonly receive low-intensity statin therapy.
- REAL-CAD is a practice-changing trial, suggesting that the administration of maximum tolerable doses of statins, within the range of local approval, would be the preferred statin strategy in patients with established coronary artery disease regardless of baseline low-density lipoprotein cholesterol levels.
was determined by the study statistician. This is an open-label trial. However, the independent event committee adjudicated all the end point events while blinded to the assigned group (online-only Data Supplement).

During follow-up, the patients’ visits dictated by the protocol were at 6 and 12 months in the first year and every 12 months thereafter. Serum lipid levels such as LDL-C, total cholesterol, triglycerides, and high-density lipoprotein cholesterol, as well as other blood tests such as creatine kinase, alanine aminotransferase, aspartate aminotransferase, creatinine, and hemoglobin A1c, were to be measured at baseline, at 6 and 12 months, and yearly thereafter, whereas high-sensitivity C-reactive protein (hsCRP) was to be measured at baseline and at 6 months.

The site investigators reported follow-up information through the web-based electronic data capturing system. Data were monitored by the data center, and the logical inconsistencies were resolved by queries. Final clinical follow-up data were collected through January to March 2016. From 2012 to 2016, site audits were performed for 3914 patients from 28 centers, and the independent data monitoring committee regularly assessed the safety aspect of study conduct.

End Points
The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization. Cardiovascular death consisted of cardiac death, including sudden death and cardiac procedure-related death, as well as noncardiac vascular death. Death without obvious noncardiovascular cause was regarded as cardiovascular death. Myocardial infarction was defined as described by the Academic Research Consortium (ARC). A secondary composite end point including coronary revascularization was defined as a composite of the primary end point event and clinically indicated coronary revascularization, excluding target-lesion revascularization for lesions treated at prior percutaneous coronary intervention. Target-lesion revascularization was not included in this secondary end point because it was unknown whether statins are effective in preventing restenosis and/or thrombosis of lesions treated at prior percutaneous coronary intervention. Other secondary end points and the details for the definitions of end points are described in the online-only Data Supplement.

The study also evaluated adverse events that developed after the start of the assigned treatment and for which a causal relationship to study drug administration could not be ruled out. Adverse events were assessed and reported by the site investigators.

Statistical Analysis
From the previous trials of more versus less statins, we hypothesized that the present study would show 16% relative risk reduction with the high-dose pitavastatin treatment. A total of 1033 events would be required to detect a 16% relative risk reduction with 80% statistical power and a 2-sided $\alpha$ of 5%. Assuming an annual event rate of 2.5% based on the previous Japanese studies and an estimated dropout rate of 10%, a total of 12,600 patients would be required to achieve 1033 events during the planned 3 years of enrollment and at least 3 years of follow-up.

The actual event rate was lower than anticipated. However, on October 27, 2015, the steering committee decided not to extend the study further despite the original event-driven trial design because a substantial number of centers were reluctant to extend the study further.

The cumulative incidence of clinical events was estimated by the Kaplan-Meier method and compared by the log-rank test. The effect of the high-dose pitavastatin relative to the low-dose pitavastatin was assessed by the Cox proportional hazard model and was expressed as hazard ratio with 95% confidence interval. Proportional hazard assumptions were assessed on the plots of log (time) versus log $[-\log (\text{survival})]$, and the assumptions were verified. Adherence to the study drug was assessed by the time-to-event analysis in which nonadherence was regarded as the event. Nonadherence to the study drug included <50% intake of the study drug, discontinuation of the assigned treatment, and loss of the drug adherence data.

Safety analyses were conducted using the data from all enrolled patients who had received at least 1 dose of pitavastatin and for whom postdose data were available (safety analysis set). Efficacy analyses were conducted after the exclusion of those patients who were randomized but were found not to meet the eligibility criteria (full analysis set). We conducted a sensitivity analysis in the safety analysis set population without exclusion of those randomized patients who did not meet inclusion and exclusion criteria. Patients lost to follow-up were censored at the time when their final clinical follow-up information was available. Number needed to treat during the 5-year follow-up was estimated from the event rate at 4 years because the number of patients at risk decreased substantially at 5 years.

We performed subgroup analyses for the primary and secondary composite end points in several prespecified subgroups. The formal interaction test was performed between the subgroup factors and the effect of the high-dose pitavastatin relative to the low-dose pitavastatin. Time-varying measurements such as LDL-C were analyzed with the generalized estimating equation models with robust variance adjustment and compound symmetry structure used as the initial assumption. Triglycerides and hsCRP were analyzed after log transformation. For describing the time profile, the average value (least-squares means) including the baseline was estimated for each of the groups with time-group interaction terms as covariates in the generalized estimating equation model for accommodating missing values. Time variables were modeled as categorical (dummy) variables. Group difference (treatment effect) and time-group interaction after the intervention were estimated with time, group, time-interaction and the baseline value as covariates. The formal interaction test was performed between the subgroup factors and the effect of the high-dose pitavastatin relative to the low-dose pitavastatin. The cumulative incidence of clinical events was estimated by the Kaplan-Meier method and compared by the log-rank test. The effect of the high-dose pitavastatin relative to the low-dose pitavastatin was assessed by the Cox proportional hazard model and was expressed as hazard ratio with 95% confidence interval. Proportional hazard assumptions were assessed on the plots of log (time) versus log $[-\log (\text{survival})]$, and the assumptions were verified. Adherence to the study drug was assessed by the time-to-event analysis in which nonadherence was regarded as the event. Nonadherence to the study drug included <50% intake of the study drug, discontinuation of the assigned treatment, and loss of the drug adherence data.

Safety analyses were conducted using the data from all enrolled patients who had received at least 1 dose of pitavastatin and for whom postdose data were available (safety analysis set). Efficacy analyses were conducted after the exclusion of those patients who were randomized but were found not to meet the eligibility criteria (full analysis set). We conducted a sensitivity analysis in the safety analysis set population without exclusion of those randomized patients who did not meet inclusion and exclusion criteria. Patients lost to follow-up were censored at the time when their final clinical follow-up information was available. Number needed to treat during the 5-year follow-up was estimated from the event rate at 4 years because the number of patients at risk decreased substantially at 5 years.

We performed subgroup analyses for the primary and secondary composite end points in several prespecified subgroups. The formal interaction test was performed between the subgroup factors and the effect of the high-dose pitavastatin relative to the low-dose pitavastatin. Time-varying measurements such as LDL-C were analyzed with the generalized estimating equation models with robust variance adjustment and compound symmetry structure used as the initial assumption. Triglycerides and hsCRP were analyzed after log transformation. For describing the time profile, the average value (least-squares means) including the baseline was estimated for each of the groups with time-group interaction terms as covariates in the generalized estimating equation model for accommodating missing values. Time variables were modeled as categorical (dummy) variables. Group difference (treatment effect) and time-group interaction after the intervention were estimated with time, group, time-interaction and the baseline value as covariates. The baseline value was included in the model for reducing bias and variability resulting from the regression to the mean. Missing values were not imputed in the analyses.

Dr Ohashi was responsible for the analysis results as the statistician for this trial. All statistical analyses were conducted with SAS System Release 9.4 software. All $P$ values are 2 sided.

The Steering Committee (online-only Data Supplement) designed the trial. All authors agreed to submit the manuscript for publication and vouch for adherence to the study.
RESULTS

Study Patients

From January 31, 2010, to March 31, 2013, a total of 14,774 patients were enrolled from 733 academic and general hospitals and clinics across Japan. After completion of the run-in period, 13,054 patients were randomized to either high-dose (n=6,526) or low-dose (n=6,528) pitavastatin. The safety analysis population consisted of 12,818 patients (high-dose, n=6,390; low-dose, n=6,428) after the exclusion of those patients who withdrew consent or for whom written informed consent was missing at the time of the site audits. The full analysis population consisted of 12,413 patients (high-dose, n=6,199; low-dose, n=6,214) after the exclusion of those patients who were found not to meet the eligibility criteria. The median follow-up period for the survivors was similar for the high-dose and low-dose groups (3.9 [range, 0.0–5.8] years and 3.9 [range, 0.0–5.9] years; P=0.08). Follow-up at 1 year was completed in 5,607 patients (97.0%) in the high-dose group and in 5,809 patients (96.9%) in the low-dose group. Final follow-up data beyond January 2016 were available for 5,171 patients (83.4%) and for 5,169 patients (83.2%), respectively (Figure 1). The rate of adherence to the study drug was high in both groups, although it was slightly but significantly lower in the high-dose group than in the low-dose group (97.1% and 98.7% at 6 months, 74.8% and 76.8% at 4 years; P=0.02; Figure I in the online-only Data Supplement).

The study population represented typical Japanese patients with stable CAD, with advanced age and a preponderance of male sex. Hypertension was present in 76% of patients and diabetes mellitus in 40%. A total of 51% had prior myocardial infarction, and 90% had prior coronary revascularization predominantly by percutaneous coronary intervention. For baseline medications, antiplatelet therapy, including dual therapy, was widely used, whereas the use of β-blockers was less prevalent. The baseline characteristics and medications were well balanced between the 2 groups (Table 1).

Lipid Parameters and hsCRP

The mean LDL-C before enrollment was 93 mg/dL with 91% of patients taking statins. The baseline LDL-C level after the run-in period was 87.7 and 88.1 mg/dL in the high-dose and low-dose groups, respectively. At 6 months, the LDL-C level was reduced by 16% (73.7

Figure 1. Disposition of patients. The reasons for not meeting the eligibility criteria were not mutually exclusive. ACS indicates acute coronary syndrome; FAS, full analysis set; LDL-C, low-density lipoprotein cholesterol; and SAS, safety analysis set.
Table 1. Baseline Characteristics

| Variable                                                                 | Pitavastatin 1 mg (n=6214) | Pitavastatin 4 mg (n=6199) |
|--------------------------------------------------------------------------|----------------------------|---------------------------|
| Age, y                                                                    | 68.1 (8.3)                 | 68.0 (8.3)                |
| Male, n (%)                                                               | 5124 (82.5)                | 5129 (82.7)               |
| Weight, kg                                                                | 65.1 (11.3) (n=5874)*      | 65.2 (11.2) (n=5822)*     |
| Body mass index, kg/m²                                                     | 24.6 (3.4) (n=5771)*       | 24.6 (3.3) (n=5710)*      |
| Abdominal circumference, cm                                               | 88.0 (9.6) (n=5069)*       | 88.1 (9.3) (n=5038)*      |
| Systolic blood pressure, mmHg                                              | 127.4 (16.1) (n=6008)*     | 127.8 (16.2) (n=5967)*    |
| Diastolic blood pressure, mmHg                                             | 72.9 (10.8) (n=6008)*      | 73.0 (10.8) (n=5967)*     |
| Heart rate, bpm                                                           | 69.6 (11.4) (n=5780)*      | 69.5 (11.7) (n=5730)*     |
| Left ventricular ejection fraction, %                                     | 60.0 (11.5) (n=3203)*      | 60.3 (11.6) (n=3192)*     |
| Cardiovascular history                                                     |                            |                           |
| History of acute coronary syndrome, n (%)                                 | 4465 (71.9)                | 4450 (71.8)               |
| Duration from acute coronary syndrome to randomization, y                | 5.1 (5.3) (n=4389)*        | 4.9 (5.1) (n=4377)*       |
| Acute coronary syndrome within 1 y before randomization, n (%)           | 1503 (24.2)                | 1494 (24.1)               |
| Hospitalization for unstable angina, n (%)                               | 1566 (25.2)                | 1601 (25.8)               |
| Myocardial infarction, n (%)                                              | 3225 (51.9)                | 3159 (51.0)               |
| Coronary revascularization, n (%)                                         | 5625 (90.5)                | 5601 (90.4)               |
| Duration from revascularization to randomization, y                      | 3.9 (4.2) (n=5567)*        | 3.9 (4.2) (n=5542)*       |
| Revascularization within 1 y before randomization, n (%)                 | 1722 (27.7)                | 1717 (27.7)               |
| Percutaneous coronary intervention, n (%)                                 | 5170 (83.2)                | 5190 (83.7)               |
| Coronary artery bypass grafting, n (%)                                    | 796 (12.8)                 | 778 (12.6)                |
| Congestive heart failure, n (%)                                           | 338 (5.4)                  | 312 (5.0)                 |
| Atrial fibrillation, n (%)                                                | 388 (6.2)                  | 382 (6.2)                 |
| Ischemic stroke, n (%)                                                    | 429 (6.9)                  | 421 (6.8)                 |
| Hemorrhagic stroke, n (%)                                                 | 76 (1.2)                   | 64 (1.0)                  |
| Peripheral vascular disease, n (%)                                        | 458 (7.4)                  | 409 (6.6)                 |
| Current smoking, n (%)                                                    | 989 (15.9)                 | 1042 (16.8)               |
| Diabetes mellitus, n (%)                                                  | 2488 (40.0)                | 2490 (40.2)               |
| Hypertension, n (%)                                                       | 4688 (75.4)                | 4708 (75.9)               |
| Family history of coronary artery disease, n (%)                          | 1050 (16.9)                | 997 (16.1)                |
| History of malignancy, n (%)                                              | 345 (5.6)                  | 315 (5.1)                 |
| Blood examinations                                                        |                            |                           |
| Total cholesterol, mg/dL                                                  | 166.8 (24.5) (n=6176)*     | 166.8 (24.1) (n=6153)*    |
| LDL-C, mg/dL                                                              | 88.1 (18.9)                | 87.7 (19.0)               |
| HDL-C, mg/dL                                                              | 50.7 (12.7) (n=6212)*      | 50.7 (12.5) (n=6190)*     |

Table 1. Continued

| Variable                                                                 | Pitavastatin 1 mg (n=6214) | Pitavastatin 4 mg (n=6199) |
|--------------------------------------------------------------------------|----------------------------|---------------------------|
| Triglycerides, mg/dL (median)†                                           | 124 (89–173) (n=6208)*     | 124 (89–177) (n=6195)*    |
| Apolipoprotein A1, mg/dL                                                 | 135.7 (24.7) (n=947)*      | 135.7 (24.8) (n=968)*     |
| Apolipoprotein B, mg/dL                                                  | 80.2 (15.4) (n=948)*       | 80.0 (15.3) (n=967)*      |
| High-sensitivity C-reactive protein (median), mg/L†                       | 0.52 (0.25–1.22) (n=6032)* | 0.51 (0.24–1.15) (n=5994)* |
| 22.0 mg/dL, n (%)                                                        | 894 (14.8)                 | 862 (14.4)                |
| Glucose, mg/dL                                                           | 123.6 (40.6) (n=5023)*     | 124.6 (40.0) (n=4997)*    |
| Hemoglobin A₁, %                                                         | 5.86 (0.85) (n=5777)*      | 5.86 (0.86) (n=5712)*     |
| In patients with diabetes mellitus, %                                    | 6.48 (0.93) (n=2410/2488)* | 6.46 (0.92) (n=2389/2490)*|
| Creatine kinase, U/L                                                     | 125.9 (90.3) (n=5894)*     | 126.3 (92.8) (n=5871)*    |
| Serum creatinine (median), mg/dL                                         | 0.87 (0.74–1.0) (n=6085)*  | 0.87 (0.74–1.0) (n=6033)* |
| eGFR, mL·min⁻¹·1.73 m⁻²§                                               | 65.8 (19.0) (n=6085)*      | 66.0 (17.3) (n=6033)*     |
| Chronic kidney disease, n (%)                                           | (n=6085)*                  | (n=6033)*                 |
| Stage 1                                                                  | 434 (7.1)                  | 468 (7.8)                 |
| Stage 2                                                                  | 3450 (56.7)                | 3426 (56.8)               |
| Stage 3                                                                  | 2097 (34.5)                | 2042 (33.8)               |
| Stage 4                                                                  | 94 (1.5)                   | 92 (1.5)                  |
| Stage 5                                                                  | 10 (0.2)                   | 5 (0.1)                   |
| Statins before run-in period                                             | (n=2410/2488)*             | (n=2389/2490)*            |
| Aspirin                                                                  | 5239 (92.5)                | 5255 (92.4)               |
| Thienopyridine                                                           | 2719 (47.2)                | 2685 (47.2)               |
| Dual antiplatelet therapy                                                | 2570 (44.6)                | 2500 (43.9)               |
| β-Blocker                                                                | 2443 (42.4)                | 2364 (41.5)               |
| Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker | 3891 (67.6)                | 3830 (67.3)               |

Data are n (%), median (interquartile range), or mean (SD). No significant differences were noted between the groups.

eGFR indicates estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol.

*For the variables with missing values, we indicated the number of patients evaluated.

†Values were derived from central laboratory measurements. If a value from central laboratory measurement was missing or not calculable, a value obtained from insurance-covered measurement was used instead. If any value other than those centrally measured was missing, that value was not imputed from other data but was handled as a missing value and excluded from analysis. Central laboratory measurements at baseline were available for LDL-C in 11813 patients and for total cholesterol, triglycerides, HDL-C, and high-sensitivity C-reactive protein in 12026 patients.

‡Values were calculated with the Friedewald equation: LDL-C=total cholesterol−(HDL-C+triglycerides/5) when triglyceride values are <400 mg/dL.

§eGFR was calculated by the following formula for Japanese patients. eGFR (male)=194×serum creatinine⁻¹·204×age⁻0·207, and eGFR (female)=194×serum creatinine⁻¹·204×age⁻0·207×0.739.
mg/dL) in the high-dose group and was unchanged (89.4 mg/dL) in the low-dose group (Figure 2). During the entire course of follow-up, LDL-C in the high-dose group was lower by 14.7 mg/dL than in the low-dose group. Total cholesterol and triglyceride levels were also significantly lower and high-density lipoprotein cholesterol level was significantly higher in the high-dose group than in the low-dose group (Figure 2).

The level of hsCRP was similar and low in both the high-dose and low-dose groups (0.57 and 0.59 mg/L) at baseline but was significantly lower in the high-dose group than in the low-dose group at 6 months (0.49 and 0.59 mg/L; Figure 2). Blood pressure and hemoglobin A1c were well controlled and similar in both groups during follow-up (Figure II in the online-only Data Supplement).

**Clinical Outcomes**

High-dose compared with low-dose pitavastatin significantly reduced the primary end point. The primary end point occurred in 266 patients (4.3%) in the high-dose group and 334 patients (5.4%) in the low-dose group (hazard ratio, 0.81; 95% confidence interval, 0.69–0.95; \( P = 0.01 \); Table 2). The cumulative 4-year incidence of the primary end point was significantly lower in the high-dose group than in the low-dose group (4.6% and 5.6%; \( P = 0.01 \); Figure 3 and Table 2). The number needed to treat for the prevention of 1 primary end point event was 63 during the 5 years of follow-up. In the sensitivity analysis without exclusion of those randomized patients who did not meet inclusion and exclusion criteria, the magnitude...
of risk reduction by high-dose pitavastatin for the primary end point (hazard ratio, 0.81; 95% confidence interval, 0.69–0.95, \(P=0.01\)) was consistent with that in the main analysis.

High-dose compared with low-dose pitavastatin also significantly reduced the secondary composite end point, including coronary revascularization, which occurred in 489 patients (7.9%) in the high-dose group and 600 patients (9.7%) in the low-dose group (hazard ratio, 0.83; 95% CI, 0.73–0.93; \(P=0.002\); Table 2). The cumulative 4-year incidence of this secondary end point was also significantly lower in the high-dose group than in the low-dose group (8.5% and 10.4%; \(P=0.002\)) with a number needed to treat of 41 during the 5 years of follow-up (Figure 3 and Table 2).

High-dose pitavastatin also significantly reduced the risks of several other secondary end points such as all-cause death, myocardial infarction, and clinically indicated coronary revascularization. There was no significant difference in the risk of ischemic stroke, hemorrhagic stroke, or unstable angina requiring emergency hospitalization (Table 2).

The risk reduction for the primary end point and for the secondary composite end point, including coronary revascularization, by the high-dose pitavastatin was consistent across all the prespecified subgroups such as age \((\geqslant 65 \text{ and } <65 \text{ years})\), sex, diabetes mellitus, baseline LDL-C \((\geqslant 95 \text{ and } <95 \text{ mg/dL})\), high-density lipoprotein cholesterol \(>40 \text{ and } \leqslant 40 \text{ mg/dL}\), triglycerides \((\geqslant 150 \text{ and } <150 \text{ mg/dL})\), and hsCRP levels \((\geqslant 1 \text{ and } <1 \text{ mg/L})\) and body mass index \((\geqslant 25 \text{ and } <25 \text{ kg/m}^2)\) without any significant interaction between the subgroup factors and the effect of high-dose pitavastatin (Figure 4). The magnitude of risk reduction by the high-dose pitavastatin in the low baseline LDL cholesterol subgroup was comparable to that in the high baseline LDL cholesterol subgroup.

The rates of serious adverse events, including rhabdomyolysis, were low and did not differ between the 2 groups, although muscle complaints were reported more often in the high-dose group than in the low-

### Table 2. Primary and Secondary End Points

| Outcomes                                                                 | Patients With Event, n (%) | Cumulative 4-y Incidence (95% Confidence Interval), %* | Hazard Ratio (95% Confidence Interval)† | \(P\) Value† |
|--------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------|----------------------------------------|--------------|
| Primary end point: a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization | 334 (5.4) 5.6 (5.0–6.3) 266 (4.3) 4.6 (4.0–5.2) | 0.81 (0.69–0.95) |                                   | 0.01         |
| Composite of primary end point or coronary revascularization             | 600 (9.7) 10.4 (9.8–11.2) | 489 (7.9) 8.5 (7.7–9.3) | 0.83 (0.73–0.93)                   | 0.002        |
| Death resulting from any cause                                           | 260 (4.2) 4.2 (3.7–4.8)   | 207 (3.3) 3.7 (3.2–4.3) | 0.81 (0.68–0.98)                  | 0.03         |
| Cardiovascular death                                                     | 112 (1.8) 1.8 (1.5–2.2)   | 86 (1.4) 1.5 (1.2–1.9) | 0.78 (0.59–1.04)                  | 0.09         |
| Cardiac death                                                           | 85 (1.4) 1.3 (1.0–1.7)    | 62 (1.0) 1.0 (0.8–1.4) | 0.75 (0.54–1.03)                  | 0.08         |
| Myocardial infarction                                                    | 72 (1.2) 1.3 (1.0–1.6)    | 40 (0.6) 0.8 (0.5–1.0) | 0.57 (0.38–0.83)                  | 0.004        |
| Ischemic stroke                                                          | 83 (1.3) 1.4 (1.1–1.8)    | 84 (1.4) 1.4 (1.1–1.8) | 1.03 (0.76–1.40)                  | 0.84         |
| Hemorrhagic stroke                                                       | 30 (0.5) 0.5 (0.3–0.7)    | 43 (0.7) 0.8 (0.6–1.1) | 1.46 (0.92–2.33)                  | 0.11         |
| Unstable angina requiring emergency hospitalization                      | 90 (1.4) 1.6 (1.3–2.0)    | 76 (1.2) 1.3 (1.0–1.6) | 0.86 (0.63–1.17)                  | 0.34         |
| Coronary revascularization (all)                                         | 626 (10.1) 11.1 (10.2–12.0) | 529 (8.5) 9.2 (8.5–10.1) | 0.86 (0.76–0.96)                  | 0.008        |
| Coronary revascularization (nontarget-lesion revascularization)          | 356 (5.7) 6.4 (5.7–7.1)   | 277 (4.5) 4.9 (4.3–5.5) | 0.79 (0.68–0.92)                  | 0.003        |
| Coronary revascularization (target-lesion revascularization)             | 319 (5.1) 5.6 (5.0–6.3)   | 276 (4.5) 4.8 (4.3–5.5) | 0.88 (0.75–1.03)                  | 0.12         |

Event rates were calculated as number of patients with the event divided by number of patients in the full analysis set population.

For the secondary composite end point, coronary revascularization excludes target-lesion revascularization for lesions treated at prior percutaneous coronary intervention.

* Cumulative 4-year incidence was estimated using the Kaplan-Meier method.
† Hazard ratios and \(P\) value were estimated using the univariate Cox proportional hazard model.
dose group. However, the rate of creatine kinase elevation $\geq 5$ the upper limit of normal did not differ between the 2 groups. There was no between-group difference in the new onset of diabetes mellitus (Table 3). Study drug discontinuation was slightly but significantly more frequent in the high-dose group than in the low-dose group (9.8% and 8.1%; $P<0.001$).

DISCUSSION

The main finding in the present study was that cardiovascular events were significantly reduced by high-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy in Japanese patients with stable CAD.

REAL-CAD is the largest-ever trial of more versus less statins, and the first trial of this type conducted in Asia. The results from the present trial were fully consistent with the results of the TNT trial (Treating to New Targets) comparing atorvastatin 80 mg with atorvastatin 10 mg in patients with stable CAD, which demonstrated that higher-dose statin therapy was associated with lower risk for cardiovascular events. The magnitude of relative risk reduction for the primary end point in the present study was comparable to that seen in European and North American trials of more versus less statins, suggesting that more intensive statins therapy could also be beneficial in Japanese patients. However, absolute risk reduction in the present study was substantially smaller than that observed in the TNT trial, reflecting the overall low event rate in Japanese patients. The very low level of hsCRP in this study is consistent with findings from previous Japanese studies and further reflective of the lower cardiovascular risk in Japanese patients with stable CAD.

REAL-CAD is a pragmatic physician-initiated trial exploring the optimal dose of statins for patients with established stable CAD within the range of approved doses in Japan. Despite current guidelines recommendations, rates of use of high-intensity statin therapy (atorvastatin 40/80 mg, rosuvastatin 20/40 mg) in patients with established CAD have been reported to be low in Asia (0%–25%). It is important to note that the statin dose in the high-dose group (pitavastatin 4 mg/d) in this study is equivalent to atorvastatin 20 mg/d in terms of LDL-C lowering, indicating that high-dose pitavastatin therapy in this study is what is generally considered moderate-intensity statin therapy in the international medical community. Most of the doses of high-intensity statin therapy defined in the American College of Cardiology/American Heart Association guideline are not approved in Japan. Furthermore, maximum approved doses of statins are prescribed very infrequently in Japan, even for secondary prevention. The mean LDL-C before the run-in period was 93 mg/dL with 91% of patients taking statins, which decreased to 88 mg/dL after the run-in period on pitavastatin 1 mg. This minimal decrease in LDL-C during the run-in period suggests that the standard of care in Japan was low-intensity statin therapy, highlighting the results of the present study as practice changing. The present study clearly demonstrated that, even in a dose range lower than the dose levels defined as high-intensity statin therapy, the higher statin dose was associated with greater protection from cardiovascular events than the lower statin dose. Furthermore, the favorable effect of high-dose pitavastatin was observed regardless of the baseline LDL-C level dichotomized as $\geq 95$ and $<95$ mg/dL.

The present study also suggested the mortality benefit with high-dose relative to low-dose pitavastatin. We are conservative about placing too much emphasis on the observed mortality benefit because the present study did not have adequate power for evaluating the
mortality difference and we cannot rule out the possibility of chance in this nonhierarchical multiple comparison for secondary end points. Furthermore, no single previous trials of more versus less statins has demonstrated mortality benefit. However, the present study is the largest-ever trial of more versus less statins, and its results appear to favor high-dose pitavastatin from the perspective of mortality. This study thus suggests

Table 3. Adverse Events and Laboratory Test Abnormalities

| Event                                           | Pitavastatin 1 mg (n=6428), n (%) | Pitavastatin 4 mg (n=6390), n (%) | P Value |
|------------------------------------------------|-----------------------------------|-----------------------------------|---------|
| Adverse events                                  |                                   |                                   |         |
| Rhabdomyolysis*                                 | 1 (0.0)                           | 2 (0.0)                           | 0.62    |
| Muscle complaints                               | 45 (0.7)                          | 121 (1.9)                         | <0.001  |
| Gallbladder-related events                      | 2 (0.0)                           | 1 (0.0)                           | 1.0     |
| Cholecystectomy                                 | 0 (0.0)                           | 0 (0.0)                           |         |
| New onset of diabetes mellitus†                 | 279 (4.3)                         | 285 (4.5)                         | 0.76    |
| Psychiatric disorders                           | 2 (0.0)                           | 3 (0.0)                           | 0.69    |
| Laboratory test abnormalities                   |                                   |                                   |         |
| Elevation of alanine aminotransferase, aspartate aminotransferase, or both ≥3 upper limit of normal range | 174 (2.7)                         | 187 (2.9)                         | 0.46    |
| Elevation of creatine kinase ≥5 upper limit of normal range | 40 (0.6)                          | 42 (0.7)                          | 0.83    |

*Rhabdomyolysis was adjudicated as >10 times elevation of creatine kinase compared with upper limit of normal range and/or clinical course compatible with rhabdomyolysis.
†New-onset diabetes mellitus was defined as hemoglobin A1c ≥6.4% at least once during follow-up in patients without diagnosis of diabetes mellitus at randomization.
that the administration of maximum tolerable doses of statins, within the range of local approval, should be the preferred statin strategy in patients with established CAD regardless of baseline LDL-C levels.

Our study has several important limitations. First, the present study was conducted as an open-label trial with its inherent limitations. However, to somewhat compensate for the open-label trial design, the primary end point was defined as not including coronary revascularization procedures because the decision for coronary revascularization is made by physicians who know the assigned treatment group. Second, the present study was terminated prematurely despite the original event-driven trial design, although we observed significant risk reduction for the primary end point. Third, final follow-up was not completed in a substantial proportion of patients, a potential limitation of physician-initiated studies that rely on voluntary efforts by the site investigators. However, the follow-up rates were comparable between the high- and low-dose groups, suggesting that the patients lost to follow-up would have affected the trial outcome in the same manner in both groups. Finally, the higher rate of study drug discontinuation and the lower rate of adherence to the study drug in the high-dose group might have nullified some of the effect of high-dose relative to low-dose therapy.

CONCLUSIONS

High-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in Japanese patients with stable CAD.

ARTICLE INFORMATION

Received November 6, 2017; accepted February 28, 2018.

The online-only Data Supplement, podcast, and transcript are available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.117.032615/-/DC1.

Correspondence

Takashi Kimura, MD, PhD, Professor of Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho Shogoin Sakyoku, Kyoto, Japan; or Teruo Inoue, MD, PhD, Professor of Department of Cardiovascular Medicine, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan. E-mail taketaka@kuhp.kyoto-u.ac.jp or inouet@dokkyomed.ac.jp

Affiliations

Department of Cardiology, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan (T.T.). Teikyo Academic Research Center, Teikyo University, Tokyo, Japan (S.I., T. Kaneko). Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (H.I., K.M., H.D.). Department of Cardiology, Aichi Medical University, Nagakute, Japan (H.T.). Department of Cardiology, National Hospital Organization Kyoto Medical Center, Japan (M.A.). Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (E.A.). Department of Cardiovascular Medicine, Hokuto Social Medical Corp, Hokuto Hospital, Oshiro, Japan (T.O.). Department of Cardiology, Fujita Health University School of Medicine, Toyoake, Japan (Y. Ozaki). Caress Sapporo Hekko Memorial Clinic, Sapporo, Japan (I.S.). Department of Cardiology, Tenri Hospital, Japan (Y.N.). Division of Cardiology, Yokohama City University Medical Center, Japan (K.H., K. Kimura). Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan (T.H., A.H.). Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Japan (Y.F.). Department of Cardiovascular Medicine, Kumamoto University Hospital, Japan (S.H.). Clinical Research Support Center, University of Tokyo Hospital, Japan (T.Y.). Department of Cardiovascular Medicine, Okayama University, Graduate School of Medicine, Japan (H.I.). Second Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan (Y. Otsuji). Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (J.T., H.S.). Cardiovascular Center, Fukushima Sanno Hospital, Japan (H.Y.). Department of Neurology, Tokyo Women’s Medical University, Tokyo, Japan (K. Kitaoka). Department of Neurology, University of Occupational and Environmental Health, School of Medicine, Chiba, Japan (M. Matsuzaki). Jichi Medical University, Shimotsuke, Japan (R.N.).

Acknowledgments

The authors thank all patients and investigators who participated in this study; Yoji Mitadera, Katsura Nakajima, and other members of the Public Health Research Foundation for their assistance as the administrative office; Teikyo Academic Research Center for its function as a data center; and Mieko Onuki, Yuna Yasuda, and other members of EDIT, Inc (Tokyo, Japan) for medical-writing support.

Sources of Funding

The Comprehensive Support Project for Clinical Research of Lifestyle-Related Disease of the Public Health Research Foundation funded this study. The company manufacturing the study drug (Kowa Pharmaceutical Co Ltd) was one of the entities providing financial support for Public Health Research Foundation projects but was not involved in design, analysis, data interpretation, or manuscript preparation.

Disclosures

Dr Taguchi received research grant from Chugai Pharmaceutical Co, Ltd, Sanwa Kagaku Kenkyusho Co, Ltd, JSPS KAKENHI Grant-in-Aid for Scientific Research, research grant, other research support, and honoraria from Public Health Research Foundation, Kowa Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd, Bayer Yakuhin, Ltd, Sanofi KK, Daiichi Sankyo Co, Ltd, Shionogi & Co, Ltd, and Mitsubishi Tanabe Pharma Co, Ltd.

MD, PhD; Yasushi Saito, MD, PhD; Takeshi Kimura, MD, PhD; Teruo Inoue, MD, PhD; Masunori Matsuura, MD, PhD; Ryozo Nagai, MD, PhD

Taguchi et al

High-Dose Versus Low-Dose Statins in Stable CAD

Circulation. 2018;137:1997–2009. DOI: 10.1161/CIRCULATIONAHA.117.032615

May 8, 2018

2006
REFERENCES

1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847. doi: 10.1161/01.CIR.97.18.1837.

2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389. doi: 10.1016/0140-6736(94)90566-5.

3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warrington JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001–1009. doi: 10.1016/0140-6736(96)90335-1.

4. West of Scotland Coronary Prevention Study Group. Influence of pravastatin on plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1997;97:1440–1445. doi: 10.1161/01.CIR.97.15.1440.

5. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357. doi: 10.1016/S0140-6736(98)01036-9.

6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22. doi: 10.1016/S0140-6736(02)09273-7.

7. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collier D, Croom-Joynson C, Dallongeville J, De Backer G, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Circulation. 2003;108:2365–2373. doi: 10.1161/01.CIR.101.14.2315.

8. Colhoun HM, Betteridge DJ, Brannigan DP, Hitman GA, Neil HAW, Liversidge AJ, Williams AD, Waters DD. Doctors' knowledge, attitudes, and compliance with the UK cholesterol treatment guidelines. Eur Heart J. 2000;21:1383–1390. doi: 10.1016/S0140-6736(00)01374-1.

9. Nissen SE, Tzonou A, Tsakos G, Wyatt SG, Nicholls JM, Luscher TF,enson MA, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials of statins. Lancet. 2010;376:1670–1681. doi: 10.1016/S0140-6736(10)61350-5.

10. Stone NJ, Robinson JG, Lichtenstein AH, Barter P, Crouse JS, Durrington PN, Emmerson M, Faergeman O, Fazio S, et al. 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504. doi: 10.1016/S0140-6736(04)68053-8.
25. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M; JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multi-center randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] study). J Am Coll Cardiol. 2009;54:293–302. doi: 10.1016/j.jacc.2009.04.033.

26. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB. A reporting system on patients evaluated for coronary artery disease: report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51(suppl):S–40. doi: 10.1161/01.CIR.51.4.5.

27. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351. doi: 10.1161/CIRCULATIONAHA.106.685313.

28. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–445. doi: 10.1016/j.jacc.2006.04.070.

29. Schoenfeld DA. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika. 1981;68:316–319. doi: 10.2307/2335833.

30. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Okawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H; J-LIT Study Group. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J. 2002;66:1096–1100. doi: 10.1253/circj.66.1096.

31. Yokoyama M, Oriasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Okawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitaoka T, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–1098. doi: 10.1016/S0140-6736(07)60527-3.

32. Japanese Coronary Artery Disease (UCAD) Study Investigators. Current status of the background of patients with coronary artery disease in Japan. Circ J. 2006;70:1256–1262. doi: 10.1253/circj.70.1256.

33. Momiyama Y, Kawaguchi A, Kajiwara I, Ohmori R, Okada K, Saito I, Konishi M, Nakamura M, Sato S, Kokubo Y, Mannami T, Adachi H, Kario K, Iso H, Ohsuzu F, Tsushima M. Prognostic value of plasma high-sensitivity C-reactive protein levels in Japanese patients with stable coronary artery disease: the Japan NCV-Collaborative Inflammation Cohort (JINC) Study. Atherosclerosis. 2009;207:272–276. doi: 10.1016/j.atherosclerosis.2009.04.015.

34. Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, Hata J, Matsumura K, Iida M, Kiyohara Y. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol. 2008;28:1385–1391. doi: 10.1161/ATVBAHA.107.157164.